Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entacapone in Combination With Imatinib Mesylate for Treatment of Patients With Gastrointestinal Stromal Tumors(GIST) Following Failure of at Least Imatinib and Sunitinib

Next Previous
Trial Profile

Entacapone in Combination With Imatinib Mesylate for Treatment of Patients With Gastrointestinal Stromal Tumors(GIST) Following Failure of at Least Imatinib and Sunitinib

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 25 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entacapone (Primary) ; Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions

Most Recent Events

  • 14 Oct 2023 The primary endpoint changed from Objective response rate(ORR) and Disease control rate(DCR) to Adverse Events (AE) And Serious Adverse Events(SAE). Hence Trial focus change from TU to AR.
  • 14 Oct 2023 Status changed from active, no longer recruiting to completed.
  • 24 Nov 2021 Planned End Date changed from 1 Jul 2020 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top